Tokyo based Kureha Launches Chronic Kidney Drug In Taiwan
This article was originally published in PharmAsia News
Executive Summary
Kureha launched chronic kidney disease therapy Kremezin in Taiwan after obtaining an approval for the drug. Currently patients have to pay out of pocket as Taiwan requires clinic trail data from two countries in order for a drug to be covered by insurance. The company is waiting for results of Phase III clinic trials jointly conducted with Mitsubushi Tanabe in Europe and the U.S. (Click here for more - Japanese language) "Kureha Launches Chronic Kidney Drug In Taiwan And Further Expand Asian Market" - Nikkan Kogyo News (8/12/08)
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.